ARTICLE | Company News
FDA approved Ocrevus ocrelizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to treat the relapsing and primary progressive forms of multiple sclerosis (PPMS). The drug is the first FDA has approved for PPMS. The CDC has estimated that about 15% of MS patients have PPMS.
Genentech spokesperson Kimberly Muscara told BioCentury that Ocrevus will be available within two weeks at a price of $65,000 per year...